High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries

Area of Science:

• Immunology
• Molecular Biology
• Drug Discovery

Background:

• Interleukin 1 (IL-1) is a key cytokine involved in inflammatory and immune responses.
• The type I IL-1 receptor mediates IL-1 signaling, making it a target for therapeutic intervention.
• Developing specific antagonists for cytokine receptors is crucial for treating inflammatory diseases.

Purpose of the Study:

• To identify novel peptide antagonists targeting the human type I IL-1 receptor.
• To characterize the binding affinity and specificity of these peptides.
• To evaluate the functional activity of these peptides in blocking IL-1-driven cellular responses.

Main Methods:

• Utilized recombinant peptide display libraries to screen for ligands binding the extracellular domain of the human type I IL-1 receptor.
• Employed affinity-selective screening to optimize peptide variants for higher binding affinity.
• Assessed peptide efficacy in blocking IL-1alpha binding and IL-1-driven responses in human and monkey cell lines.

Main Results:

• Identified two families of peptides that specifically bind the human type I IL-1 receptor.
• Developed high-affinity peptide variants with IC50 values as low as approximately 2 nM.
• Demonstrated that these peptides effectively block IL-1-driven responses in relevant cell types.
• Confirmed specificity for the human type I IL-1 receptor, with no binding to the type II IL-1 receptor or murine type I IL-1 receptor.

Conclusions:

• Successfully developed high-affinity peptide antagonists for the human type I IL-1 receptor.
• These peptides represent a novel class of cytokine receptor antagonists with potential therapeutic applications.
• This study provides the first example of a high-affinity peptide antagonist for a cytokine receptor.